| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |